Skip to content

US · CLNN · BIOTECHNOLOGY

Clene Inc. (CLNN) intrinsic value and stock valuation

$3.52as of 2026-11-21 · Mkt cap 55.46M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Clene Inc. DCF and intrinsic value

InvestorsCraft values CLNN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CLNN’s statements →

Clene Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Salt Lake City, UT 84121 clene.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$200K-1% 5y CAGRd
20172025
Net income
-$-26.17M
20172025
Free cash flow
-$-18.59M
20182025
Total equity
-$-17.59M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$200K$340K$650K$470K$720K
Operating income-$-23.08M-$-33.09M-$-40.54M-$-48.41M-$-49.98M
Net income-$-26.17M-$-39.4M-$-49.5M-$-29.92M-$-9.74M
EPSd-$-2.65M-$-5.67M-$-9.43M-$-9.18M-$-3.16M
Operating cash flow-$-18.55M-$-21.33M-$-30.17M-$-39.01M-$-34.62M
Capital expenditure-$-40K-$-10K-$-330K-$-5.18M-$-1.33M
Free cash flow-$-18.59M-$-21.34M-$-30.5M-$-44.19M-$-35.96M
Total assets$18.1M$27.3M$52.3M$44.5M$63.1M
Total debt$21.7M$20.8M$32.2M$31.8M$24M
Net debt$16.5M$8.69M$3.34M$13.5M-$-26.25M
Total equity-$-17.59M-$-8.86M$13.4M$3.24M$12.6M
Cash and short-term investments$5.19M$12.2M$35M$23.3M$50.3M
Income statement
20252024202320222021
Revenue$200K$340K$650K$470K$720K
Cost of revenue$40K$70K$120K$30K$290K
Gross profit$160K$270K$530K$450K$430K
Research and development expenses$14M$20.1M$26.7M$31.9M$28.4M
Selling, general and administrative expenses$9.23M$13.3M$14.4M$16.2M$18.8M
Other expenses$0.00$0.00$0.00$770K$3.18M
Operating expenses$23.2M$33.4M$41.1M$48.9M$50.4M
Cost and expenses$23.3M$33.4M$41.2M$48.9M$50.7M
Interest income$220K$860K$1.39M$0.00$0.00
Interest expense$2.68M$4.06M$4.56M$3.3M$870K
Depreciation and amortization$1.5M$1.65M$1.71M$1.02M$950K
Ebitda-$-22M-$-33.69M-$-43.24M-$-25.6M-$-8.34M
Operating income-$-23.08M-$-33.09M-$-40.54M-$-48.41M-$-49.98M
Total other income/expenses, net-$-3.09M-$-6.31M-$-8.96M$18.5M$39.8M
Income before tax-$-26.17M-$-39.4M-$-49.5M-$-29.92M-$-10.17M
Income tax expense$0.00$0.00$0.00$0.00-$-430K
Net income-$-26.17M-$-39.4M-$-49.5M-$-29.92M-$-9.74M
Weighted average shares outstanding$9.86M$6.95M$5.25M$3.26M$3.08M
Weighted average diluted shares outstanding$9.86M$6.95M$5.25M$3.26M$3.08M
Balance sheet
20252024202320222021
Cash and short-term investments$5.19M$12.2M$35M$23.3M$50.3M
Net receivables$590K$390K$1.34M$2.97M$1.61M
Inventory$40K$70K$40K$40K$40K
Total current assets$8.98M$16.2M$38.9M$29.2M$54.6M
Property, plant and equipment, net$9.1M$11.1M$13.4M$15.2M$8.42M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$60K$60K$0.00$60K$60K
Total non-current assets$9.15M$11.2M$13.5M$15.3M$8.48M
Total assets$18.1M$27.3M$52.3M$44.5M$63.1M
Accounts payable$890K$1.24M$1.5M$3.01M$1.92M
Short-term debt$4.88M$1.28M$20.1M$6.98M$490K
Deferred revenue$1.51M$2.67M$0.00$520K$520K
Total current liabilities$10.8M$10.3M$25.3M$13.9M$6.03M
Long-term debt$16.8M$19.6M$12.1M$24.8M$23.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$25M$25.9M$13.6M$27.4M$44.4M
Capital lease obligations$4.06M$5.06M$5.51M$6.15M$4.96M
Total liabilities$35.7M$36.2M$39M$41.3M$50.5M
Common stock$0.00$0.00$10K$10K$10K
Retained earnings-$-308.3M-$-282.12M-$-242.72M-$-193.22M-$-163.3M
Accumulated other comprehensive income (loss)$170K$70K$200K$200K$230K
Total equity-$-17.59M-$-8.86M$13.4M$3.24M$12.6M
Total investments$60K$60K$6.18M$5.04M$60K
Total debt$21.7M$20.8M$32.2M$31.8M$24M
Net debt$16.5M$8.69M$3.34M$13.5M-$-26.25M
Cash flow statement
20252024202320222021
Net income-$-26.17M-$-39.4M-$-49.5M-$-29.92M-$-9.74M
Depreciation and amortization$1.5M$1.65M$1.71M$1.02M$950K
Stock-based compensation$6.38M$7.95M$9.12M$8.51M$12.4M
Change in working capital-$-3.35M$3.21M-$-190K-$-1.54M$1M
Accounts receivable$60K$80K$50K-$-140K-$-30K
Inventory$30K-$-30K$10K-$0.00$150K
Accounts payable-$-350K-$-260K-$-1.51M$280K$1.27M
Net cash provided by operating activities-$-18.55M-$-21.33M-$-30.17M-$-39.01M-$-34.62M
Investments in property, plant and equipment-$-40K-$-10K-$-330K-$-5.18M-$-1.33M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-40K$6.32M-$-1.5M-$-10.16M-$-1.33M
Common stock issued$10.4M$9.24M$42.1M$11.5M$9.25M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11.5M-$-1.53M$42.2M$17.3M$27.1M
Net change in cash-$-6.97M-$-16.67M$10.5M-$-31.96M-$-8.93M
Cash at end of period$5.25M$12.2M$28.9M$18.4M$50.4M
Operating cash flow-$-18.55M-$-21.33M-$-30.17M-$-39.01M-$-34.62M
Capital expenditure-$-40K-$-10K-$-330K-$-5.18M-$-1.33M
Free cash flow-$-18.59M-$-21.34M-$-30.5M-$-44.19M-$-35.96M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Clene Inc.

        Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.

        CEO
        Robert Etherington
        Employees
        79
        Beta
        0.92

        Explore

        Frequently asked questions

        What is the intrinsic value of Clene Inc. (CLNN)?

        Clene Inc. (CLNN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CLNN undervalued?

        CLNN trades at a price of $3.52 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.